-
Mashup Score: 20Approach to the patient: Insulinoma - 5 month(s) ago
Abstract. Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms (panNEN) with an estimated incidence of 1-4 cases per million per year. Extrapan
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Approach to the patient: Insulinoma - 6 month(s) ago
Abstract. Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms (panNEN) with an estimated incidence of 1-4 cases per million per year. Extrapan
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
RT @DanielJDrucker: Diagnosis, localization and treatment of insulinoma #hypoglycemia https://t.co/XqpUSVRkHT
-
-
Mashup Score: 1ISPAD Clinical Practice Consensus Guidelines 2022 - International Society for Pediatric and Adolescent Diabetes - 7 month(s) ago
ISPAD in the only international society focusing on all types of diabetes in the worldwide population under 25. Help us in the global fight against diabetes in the young.
Source: www.ispad.orgCategories: Latest Headlines, PediatricsTweet-
▪️ Discover more about the assessment and management of hypoglycemia in children and adolescents with diabetes in Chapter 12 of the #ISPAD Clinical Practice Consensus Guidelines 2022! https://t.co/Yd3z9j4W6b #ISPADGuidelines2022 #Type1Diabetes #Hypo #Hypoglycemia #Children https://t.co/3jc8iXPiuY
-
-
Mashup Score: 0
Background: Inadequate dose titration and poor adherence to basal insulin can lead to suboptimal glycemic control in persons with type 2 diabetes (T2D). Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. Objective: To compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice. Design: 52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements. (ClinicalTrials.gov: NCT04760626) Setting: 176 sites in 7 countries. Participants: 1085 insulin-naive adults with T2D. Intervention: Icodec with app or OD analogue (insulin degludec, insulin glargine U100, or insulin glargine U300). Measurements: The primary outcome was change in glycated hemoglobin (HbA1c) level from baseline to week 52. Secondary outcomes included patient-reported outcomes (Treatment Related Impact
Source: www.acpjournals.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A new trial (ONWARDS 5) found that once-weekly insulin #icodec titrated with a dosing guide app demonstrated superior reduction in HbA1c levels and similarly low #hypoglycemia rates compared with once-daily #insulin: https://t.co/ULWSDxDGcY https://t.co/6I1DW9xUBY
-
-
Mashup Score: 0
Background: Inadequate dose titration and poor adherence to basal insulin can lead to suboptimal glycemic control in persons with type 2 diabetes (T2D). Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. Objective: To compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice. Design: 52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements. (ClinicalTrials.gov: NCT04760626) Setting: 176 sites in 7 countries. Participants: 1085 insulin-naive adults with T2D. Intervention: Icodec with app or OD analogue (insulin degludec, insulin glargine U100, or insulin glargine U300). Measurements: The primary outcome was change in glycated hemoglobin (HbA1c) level from baseline to week 52. Secondary outcomes included patient-reported outcomes (Treatment Related Impact
Source: www.acpjournals.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A new trial (ONWARDS 5) found that once-weekly insulin icodec titrated with a dosing guide app demonstrated superior reduction in HbA1c levels and similarly low #hypoglycemia rates compared with once-daily #insulin: https://t.co/Zw0pgyJDdL https://t.co/nvYmgwjIY5
-
-
Mashup Score: 0Login - 8 month(s) ago
New to DocMatter, or having trouble logging in? Click here to find your account Contact us for other issues, or Request to join.
Source: www.docmatter.comCategories: Endocrinology, Latest HeadlinesTweet-
Join the DocMatter discussion on the case of a woman (37) who developed #hypoglycemia-like symptoms in early 2022 after COVID infection. Symptoms progressed despite a low-carb diet and acarbose, resulting in Cushings-like symptoms: https://t.co/tmAkbH3upT
-
-
Mashup Score: 0Comprehensive Care for Persons with Diabetes: A Certificate Program - 9 month(s) ago
The Endocrine Society and the American College of Osteopathic Family Physicians have collaborated to develop a holistic certificate program that covers the many facets of diabetes care.
Source: www.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet-
We are offering a 10% discount on Comprehensive Care for Persons with Diabetes (https://t.co/7BZhxpZnJJ). Stop by booth #1104 at #ADCES2023 to learn about our #diabetes resources like our latest #hyperglycemia and #hypoglycemia guidelines (https://t.co/hRk2RcApVO) @ADCESdiabetes
-
-
Mashup Score: 0Inpatient Hyperglycemia Guideline Resources - 9 month(s) ago
We are pleased to announce the release of our latest clinical practice guideline: Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings! This new guideline reflects evolving clinical science and provides evidence-based recommendations for clinical care and practice managing hyperglycemia in the inpatient setting.
Source: www.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet-
Come meet with us to learn about our member benefits and receive complimentary copies of our latest #hyperglycemia (https://t.co/6ntsuKwaka) and #hypoglycemia (https://t.co/nN9focZ0vV) clinical practice guidelines at #ADCES2023 booth #1104: https://t.co/hRk2RcApVO @ADCESdiabetes
-
-
Mashup Score: 0
Adults with type 1 diabetes and impaired awareness of hypoglycemia have worse diabetes-related distress than those with normal hypoglycemia awareness, according to a study published in Diabetic Medicine. “Our study highlights the persistent relation between impaired awareness of hypoglycemia and diabetes distress with manifestations across emotions, cognitions and behaviors, despite the use
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#ICYMI: "Apparently, widespread use of intermittently scanned #CGM technology has not closed this gap between impaired awareness of hypoglycemia and normal awareness of #hypoglycemia." @DiabeticMed @radboudumc https://t.co/gfdWSMqtzF
-
-
Mashup Score: 0
The FDA approved an allogenic pancreatic islet cellular therapy for adults with type 1 diabetes who struggled to achieve their target HbA1c due to repeated episodes of severe hypoglycemia, according to an agency press release. The novel cell therapy (Lantidra, CellTrans Inc.) is made from deceased donor pancreatic cells and is administered as a single infusion into the patient’s hepatic
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#ICYMI: “Today’s approval, the first-ever cell therapy to treat patients with type 1 #diabetes, provides individuals living with type 1 diabetes and recurrent severe #hypoglycemia an additional treatment option." @US_FDA #diabetes #hypoglycemia https://t.co/7ymdxJsIyD
-
RT @DanielJDrucker: Diagnosis, localization and treatment of insulinoma #hypoglycemia https://t.co/XqpUSVRkHT